MetaVia is a clinical-stage biopharmaceutical company developing novel pharmaceuticals to treat cardiometabolic diseases, with two primary product candidates: Vanoglipel, a GPR119 agonist for metabolic dysfunction-associated steatohepatitis and type 2 diabetes that promotes gut peptide release to improve glucose and lipid metabolism, and DA-1726, a GLP1R and GCGR dual agonist for obesity that reduces appetite and increases energy expenditure. The company operates through research and development activities including preclinical development and clinical trials, relying on contract manufacturing partnerships while pursuing capital funding through equity offerings. MetaVia generates no product revenues and competes in the pharmaceutical industry against larger pharmaceutical companies, biotechnology firms, and research institutions, with plans to market approved product candidates internationally.